Intellia stock price target maintained at $30 by Citizens on HAE data

Citizens maintained a $30 price target on Intellia Therapeutics (NTLA) after positive data on its lonvo-z treatment for hereditary angioedema. The firm noted strong patient demand and key opinion leader interest, with a sum-of-the-parts analysis valuing the HAE opportunity at $20 per share. NTLA trades at $10.55 with a market cap of $1.48 billion. The FDA granted Priority Review to lonvo-z, with a potential approval date of March 10, 2027.

Original reporting
Published Nov 13, 2026, 9:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 9:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$NTLA
Bullish
high confidence
Mentioned
$NTLA
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NTLABullishHigh
01

Why it matters

The FDA BLA acceptance and Priority Review provide a concrete regulatory milestone that could materially affect NTLA's valuation.

02

Market read

First disclosure of FDA acceptance for a potential first‑in‑vivo CRISPR therapy, creating a near‑term trading catalyst for NTLA.

03

What to watch

Cash burn rate and upcoming financing needs may constrain upside despite regulatory progress.

Relevance 8/10Novelty 8/10Timing: today

Background

Intellia Therapeutics (NASDAQ:NTLA) is a CRISPR‑based gene‑editing company developing lonvo‑z for hereditary angioedema.

Company-level read

Ticker impact

$NTLABullishHigh confidence
Context

Citizens reiterated a $30 price target after FDA accepted Intellia's BLA for lonvo‑z and granted Priority Review, marking the first public disclosure of this regulatory step.

Expected impact

upward pressure as the market anticipates eventual approval and commercial rollout

Evidence & confidence

FDA BLA acceptance and Priority Review are material catalysts for a biotech; no comparable news has been reported yet.

Market effects

Strengthens the broader CRISPR gene‑editing sector by showing regulatory progress.

Positive for US biotech investors and related ETFs.

Limited to biotech and gene‑editing markets; no broader macro effect.

Counterpoint

If the FDA delays or requires additional data, the stock could face a sharp correction.

Key entities

  • Intellia Therapeutics

    Developer of lonvo‑z CRISPR therapy.

  • Citizens

    Equity research firm maintaining a $30 price target.

Related articles

$NTLALow

Intellia Therapeutics, Inc. (NTLA): Results of Operations and Financial Condition

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Readying Lonvo-z forPatients with HAE November 12, 2026 Exhibit 99.1 This presentation contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-lookin

$NTLAMedAI 8/10

Intellia presents lonvo-z data at allergy conference

Intellia Therapeutics (NTLA) presented positive data on its hereditary angioedema treatment, lonvo-z, at a conference. The Phase 3 HAELO trial showed an 81% decrease in monthly attack rate. The Phase 1/2 study showed 100% of patients on a 50 mg dose were free from long-term prophylaxis, with 90% attack-free after one year. The FDA accepted the Biologics License Application with a target action date of March 10, 2027.

$NTLAMed

Intellia Therapeutics Announces Third Quarter 2026 Financial Results

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be includ